MX346525B - Proceso para preparar y purificar n-benzoil-estaurosporina. - Google Patents

Proceso para preparar y purificar n-benzoil-estaurosporina.

Info

Publication number
MX346525B
MX346525B MX2011007303A MX2011007303A MX346525B MX 346525 B MX346525 B MX 346525B MX 2011007303 A MX2011007303 A MX 2011007303A MX 2011007303 A MX2011007303 A MX 2011007303A MX 346525 B MX346525 B MX 346525B
Authority
MX
Mexico
Prior art keywords
staurosporine
benzoyl
organic compounds
warm
processes
Prior art date
Application number
MX2011007303A
Other languages
English (en)
Inventor
Mutz Michael
Hoehn Pascale
Koch Bernd
Original Assignee
Novartis Ag *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346525(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag * filed Critical Novartis Ag *
Publication of MX346525B publication Critical patent/MX346525B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

La presente invención se refiere a una nueva forma cristalina II de N-benzoil-estaurosporina; a composiciones que la contienen; a procesos para su preparación; y al uso de la forma cristalina II de N-benzoil-estaurosporina en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos. La invención se refiere a las formas amorfas de N-benzoil-estaurosporina; a composiciones que las contienen; a procesos para su preparación; y al uso de la N-benzoil-estaurosporina amorfa en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos.
MX2011007303A 2004-11-05 2005-11-03 Proceso para preparar y purificar n-benzoil-estaurosporina. MX346525B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07
PCT/EP2005/011789 WO2006048296A1 (en) 2004-11-05 2005-11-03 Organic compounds

Publications (1)

Publication Number Publication Date
MX346525B true MX346525B (es) 2017-03-23

Family

ID=35501294

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011007303A MX346525B (es) 2004-11-05 2005-11-03 Proceso para preparar y purificar n-benzoil-estaurosporina.
MX2007005429A MX2007005429A (es) 2004-11-05 2005-11-03 Compuestos organicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2007005429A MX2007005429A (es) 2004-11-05 2005-11-03 Compuestos organicos.

Country Status (31)

Country Link
US (2) US8198435B2 (es)
EP (3) EP2955186A1 (es)
JP (4) JP5057986B2 (es)
KR (3) KR101333851B1 (es)
CN (2) CN102993213A (es)
AR (1) AR052322A1 (es)
AU (2) AU2005300693B2 (es)
BR (1) BRPI0517689A (es)
CA (1) CA2584911C (es)
CY (1) CY1113059T1 (es)
DK (1) DK1812448T3 (es)
EC (1) ECSP12007431A (es)
ES (1) ES2388142T3 (es)
GT (1) GT200500311A (es)
HK (2) HK1211587A1 (es)
HR (1) HRP20120652T1 (es)
IL (3) IL182691A (es)
JO (1) JO2897B1 (es)
MA (1) MA29033B1 (es)
MX (2) MX346525B (es)
MY (2) MY154878A (es)
NO (2) NO338960B1 (es)
NZ (3) NZ599033A (es)
PE (3) PE20090433A1 (es)
PL (1) PL1812448T3 (es)
PT (1) PT1812448E (es)
RU (2) RU2394038C2 (es)
SI (1) SI1812448T1 (es)
TN (1) TNSN07165A1 (es)
TW (4) TWI433852B (es)
WO (1) WO2006048296A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) * 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
US20220242880A1 (en) * 2019-06-24 2022-08-04 Dr. Reddy?s Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
ES2136103T3 (es) 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
US6878804B1 (en) 1999-08-30 2005-04-12 University Of Zurich Synthesis of template-fixed β-hairpin loop mimetics
PT1372611E (pt) 2001-03-26 2006-08-31 Novartis Ag Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
KR100407758B1 (ko) 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US7608420B2 (en) * 2003-04-22 2009-10-27 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
MX2007005429A (es) 2007-05-18
JO2897B1 (en) 2015-09-15
JP2012149099A (ja) 2012-08-09
EP2272850A3 (en) 2011-09-21
TW200628474A (en) 2006-08-16
CA2584911C (en) 2017-10-24
PE20060947A1 (es) 2006-10-30
TNSN07165A1 (en) 2008-11-21
CY1113059T1 (el) 2016-04-13
TW201247680A (en) 2012-12-01
EP2272850B1 (en) 2017-05-10
KR101289998B1 (ko) 2013-07-30
PE20130377A1 (es) 2013-04-03
RU2394038C2 (ru) 2010-07-10
JP5701246B2 (ja) 2015-04-15
KR20070083979A (ko) 2007-08-24
NO338960B1 (no) 2016-11-07
EP1812448B1 (en) 2012-05-23
KR101265850B1 (ko) 2013-05-20
US8198435B2 (en) 2012-06-12
JP2015063569A (ja) 2015-04-09
IL182691A0 (en) 2007-09-20
PE20090433A1 (es) 2009-05-05
TWI530500B (zh) 2016-04-21
TW201247681A (en) 2012-12-01
WO2006048296A1 (en) 2006-05-11
NZ554653A (en) 2010-10-29
NZ588025A (en) 2012-04-27
TWI433852B (zh) 2014-04-11
HK1211587A1 (en) 2016-05-27
JP2008518995A (ja) 2008-06-05
HK1108881A1 (en) 2008-05-23
TW201446773A (zh) 2014-12-16
IL182691A (en) 2013-02-28
RU2009137788A (ru) 2011-04-20
ECSP12007431A (es) 2012-06-29
DK1812448T3 (da) 2012-08-27
JP5057986B2 (ja) 2012-10-24
AR052322A1 (es) 2007-03-14
NO20161152A1 (no) 2007-05-30
AU2005300693B2 (en) 2010-08-19
TWI455941B (zh) 2014-10-11
PL1812448T3 (pl) 2012-10-31
CN102627658A (zh) 2012-08-08
NO20072290L (no) 2007-05-30
MY154878A (en) 2015-08-14
NO340404B1 (no) 2017-04-18
AU2009245817A1 (en) 2009-12-24
EP2955186A1 (en) 2015-12-16
US8710216B2 (en) 2014-04-29
MY147404A (en) 2012-11-30
AU2005300693A1 (en) 2006-05-11
NZ599033A (en) 2012-09-28
RU2007120695A (ru) 2008-12-10
CA2584911A1 (en) 2006-05-11
PT1812448E (pt) 2012-08-24
TWI530501B (zh) 2016-04-21
IL217571A (en) 2017-07-31
BRPI0517689A (pt) 2008-10-14
IL207702A0 (en) 2010-12-30
US20090137552A1 (en) 2009-05-28
MA29033B1 (fr) 2007-11-01
EP2272850A2 (en) 2011-01-12
CN102993213A (zh) 2013-03-27
RU2467012C2 (ru) 2012-11-20
KR20120101600A (ko) 2012-09-13
KR101333851B1 (ko) 2013-11-27
IL207702A (en) 2016-09-29
EP1812448A1 (en) 2007-08-01
SI1812448T1 (sl) 2012-09-28
AU2009245817B2 (en) 2013-02-21
JP2017061578A (ja) 2017-03-30
US20120322789A1 (en) 2012-12-20
ES2388142T3 (es) 2012-10-09
GT200500311A (es) 2006-05-22
KR20120101601A (ko) 2012-09-13
HRP20120652T1 (hr) 2012-09-30

Similar Documents

Publication Publication Date Title
TNSN07165A1 (en) Organic compounds
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
TW200626068A (en) Active compounds for seed treatment
PL381247A1 (pl) Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EP1804794A4 (en) SPIROPIPERIDINE COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2007050587A3 (en) Therapeutic compositions and methods
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
ZA200610640B (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EP1709155A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DYSPROLIFERATIVE DISEASES AND METHODS OF THEIR USE
IL184849A0 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
HU0500145D0 (en) Composition for the treatment of oral diseases
WO2006018807A8 (en) Crystalline forms of cefdinir
GB0415181D0 (en) Compounds for use in the treatment of infection
WO2008130321A3 (en) Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
WO2007057756A3 (en) Isocystene derivatives for the treatment of pain
UA91250C2 (en) 4-oxadiazolyl-piperidine compounds and use thereof
TW200738719A (en) Organic compounds